GeoVax Labs expands rights under NIH COVID-19 license to include Mpox, smallpox

GeoVax Labs has amended a previously executed Patent and Biological Materials License Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, in support of GeoVax’s development of a vaccine against SARS-CoV-2. The amendment expands GeoVax’s commercial license to include Mpox and smallpox as additional indications. The License Agreement, as amended, allows GeoVax to use these materials and patent rights owned by agencies of the United States Department of Health and Human Services in combination with the Company’s proprietary technology for the creation of preventive Modified Vaccinia Ankara Virus-Virus Like Particle vaccines that prime and/or boost the immune system against SARS-CoV-2 as well as Mpox and/or smallpox. Financial terms of the License Agreement were not disclosed.